Non-GLP-1 agents are most appropriate for patients unable to tolerate GLP-1 medications, those with GLP-1 contraindications (such as personal or family history of medullary thyroid carcinoma), or individuals requiring different metabolic pathways
In this trial, 3,183 adult patients with inadequately controlled type 2 diabetes mellitus and atherosclerotic CV disease were randomized to RYBELSUS 14 mg once daily or placebo for a median observation time of 16 months
Gene x environment (GxE) interactions We quantified the resulting GxE interaction effects by calculating the Z -score of the LFC (relative to pDNA) using cutting control guides as the null distribution, which corrects for differences in growth rates between different conditions (Supplementary Data 2)
Gloyn noted that large amounts of genetic data from clinical trials likely already exist and could help answer important questions about why some people respond poorly to GLP-1 therapies
Eating healthy, exercising regularly, and being consistent with treatment can boost the medications effect